CClinicalTrials.gg
CompletedNCT01642043Updated Aug 29, 2022

Point-of-Care Ultrasound in Greater Trochanteric Pain Syndrome

An observational study in Greater Trochanteric Pain Syndrome, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-29.

Sponsored by Massachusetts General Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Greater trochanteric pain syndrome (GTPS) is a common cause of musculoskeletal pain.

The primary aim of this study is to describe the soft tissue and bony structural ultrasound (US) findings identified in the lateral hip and iliotibial band (ITB) in patients presenting with greater trochanteric pain syndrome (GTPS) in an outpatient rheumatology clinic.

Read the detailed description

GTPS, widely known as trochanteric bursitis, encompasses a spectrum of disorders (gluteal tendinopathy, tears, bursitis, and ITB syndrome) that are difficult to distinguish by clinical exam alone. Better understanding of US imaging characteristics in relation to clinical symptoms may be helpful in identifying those patients who would most benefit from corticosteroid injections and other non-operative treatment options.

Point-of-care musculoskeletal US use has been shown to reduce repeated hospital appointments, improve accuracy of diagnosis, and provide expedited treatment, thus improving quality of care in an outpatient musculoskeletal clinic. US assessment is not routinely included in the management of GTPS patients and ideal imaging modalities are not established.

02

Conditions studied

  • Greater Trochanteric Pain Syndrome

Keywords

  • greater trochanteric pain syndrome
  • trochanteric bursitis
  • lateral hip pain
03

In context

Bursitis

411 studies on the registry are indexed under Bursitis; 112 are open to participants now.

This study's enrollment of 100 is above the median of 58 across 32 observational studies indexed under Bursitis.

Browse Bursitis studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,536 studies on the registry; 446 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Outpatient rheumatology clinic

Inclusion criteria

  • Lateral hip pain thought to be due to GTPS as evidenced by tenderness to palpation of the lateral hip over the greater trochanter
  • Have a pain score of at least 2 out of 10 on an 11-point numeric rating scale
  • Lateral hip pain for at least 1 week
  • For participants with bilateral GTPS, the most symptomatic hip will be considered the study hip
  • Have a telephone

Exclusion criteria

Exclusion Criteria:

  • Inability to give informed consent
  • BMI > 40
  • Evidence of severe OA of the study hip by X-ray
  • Avascular necrosis of the study hip
  • Groin pain at rest or with log-rolling
  • Hip internal rotation range of motion \< 15 degrees
  • Prior fracture involving the study hip or femur
  • Prior hip surgery or prosthesis in the painful hip
  • Paralysis or paresis of the lower extremity
  • Wheelchair bound
  • Open wound or skin lesions in the lateral hip
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (actual)
06

What researchers measure

Primary outcomes

  1. Descriptive diagnostic ultrasound findings of the bony and soft tissue structures of the lateral hip and iliotibial band

    Presence of tendinopathy, tendon tears, bursitis, enthesophytes, calcifications

    Time frame: Baseline

Secondary outcomes

  1. Pain with rest measured by a numeric rating scale

    Time frame: Baseline and 2 weeks

  2. Pain with activity as measured by a numeric rating scale

    Time frame: Baseline and 2 weeks

  3. Demographics- composite

    age, gender, race/ethnicity, education, occupation, comorbidities, overall health status.

    Time frame: Baseline

  4. Pressure point threshold as measured by an algometer

    Time frame: Baseline

  5. Clinical data: Predictors of treatment response- composite

    * Duration of pain * Body Mass Index * Physical exam findings * Treatments tried in the past * Presence of back pain

    Time frame: Baseline

07

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01642043
Lead sponsor
Massachusetts General Hospital
Responsible party
Minna Jean Kohler (Director, Musculoskeletal Ultrasound- Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital) — Principal investigator
First posted
Jul 17, 2012
Start date
Jun 2012
Primary completion
Aug 2015
Completion
Aug 2015
Last update
Aug 29, 2022

Study contacts

Minna J. Kohler, M.D.
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion